|
![]() |
|
|
Digoxin
drug data and news
Digoxin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Digoxin | ||
| Brand Names/Synonyms | Cardoxin; Cogoxin; Cordioxil; Davoxin; Digacin; Digitalis Glycoside; Digitekt; Digoxin; Digoxin Pediatric; Dilanacin; Dixina; Dokim; Dynamos; Eudigox; Homolle's Digitalin; Lanacordin; Lanacrist; Lanicor; Lanoxicaps; Lanoxin; Lenoxicaps; Lenoxin; Longdigox; Neo-Lanicor; Neodioxanin; Rougoxin; Sk-Digoxin; Stillacor; Vanoxin | ||
| Indication | For the treatment and management of Congestive cardiac insufficiency,arrhythmias and heart failure | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. | ||
| Mechanism Of Action | Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential. | ||
| Digoxin News (When available) |
Simplified treatment regimens show promise in HIV-infected ... Feb 6, 2006 CROI News Feature: Experts divided over the future of treatment ... Feb 9, 2006 CROI: Disappointment for glitazones, metformin and testosterone ... Feb 10, 2006 CROI: AZT, 3TC and FTC achieve good concentrations in the female ... Feb 17, 2006 Multi-component drug delivery system: An emerging trend Feb 8, 2006 RFS Pharma Announces 2-Week Data from An NIH-Sponsored Phase 2 ... Feb 14, 2006 Multi-component drug delivery system: An emerging trend Feb 8, 2006 Simplified treatment regimens show promise in HIV-infected ... Feb 6, 2006 One-pill HIV regimen outperforms gold standard Jan 19, 2006 ICAAC: Switch from AZT or d4T to tenofovir may improve blood fat ... Jan 13, 2006 Health Beat Jan 26, 2006 Most people given non-occupational PEP fully adhere to their ... Jan 19, 2006 John Beale Jan 19, 2006 Antiretrovirals To Remain in Short Supply if Steps Not Taken, WHO ... Nov 14, 2005 Worldwide Shortage of Glaxo's AIDS Drug, AZT, Alarms Patients ... Nov 10, 2005 Psychiatric Manifestations of HIV Infection and AIDS Dec 5, 2005 Gilead's Truvada Better at Suppressing HIV Than GSK's Combivir ... Nov 21, 2005 Number of Pills Affects Adherence to HIV Treatment Regimens Nov 30, 2005 Number of Pills Affects Adherence to HIV Treatment Regimens Nov 30, 2005 Looming AZT Shortage Could Cut Availability of Anti-Aids Drugs Nov 11, 2005 Pharma RFID Opportunity Nov 8, 2005 GlaxoSmithKline's Patent on Retrovir Expires; Generic Versions of ... Sep 20, 2005 Generic AZT Hits the United States Oct 10, 2005 FDA clears generic of Glaxo's Retrovir for overseas use Sep 9, 2005 Triangle on front lines of evolving war on AIDS Sep 18, 2005 First HIV Drug, Glaxo's AZT, Gets Generic US Rivals (Update1) Sep 19, 2005 10:19 am: Indian company says it has US FDA approval to produce ... Sep 20, 2005 FDA Approves Four Generic Forms of Zidovudine for US Sales After ... Sep 21, 2005 FDA OKs generic versions of AIDS drug Sep 21, 2005 Aurobindo Receives Tentative FDA Approval To Produce Generic ... Sep 12, 2005 FDA OKs Generic Versions of AIDS Drug Sep 20, 2005 Glaxo’s patent on AZT expires Sep 20, 2005 FDA Approves Generic Versions of HIV Drug Sep 21, 2005 AZT goes generic Sep 22, 2005 Teva USA Introduces Zidovudine Tablets Sep 23, 2005 More National News... Sep 30, 2005 Govt Overcomes ARV Shortage Oct 6, 2005 AIDS Generic Drugs Approved by FDA for Sale in US Sep 21, 2005 Ranbaxy wins USFDA clearance for AIDS drugs Sep 20, 2005 Ranbaxy Receives Approval to Market Zidovudine Tablets Sep 20, 2005 Aurobindo AIDS drug gets US FDA approval Sep 12, 2005 Ranbaxy gets USFDA approval for Zidovudine Sep 20, 2005 FDA Approves First Pediatric Generic AIDS Drug for US Marketing Sep 20, 2005 Ranbaxy gets FDA OK for HIV drug Sep 20, 2005 FDA Approves Generic AIDS Drugs For First Time Sep 20, 2005 FDA Approves First Generic AIDS Drugs for Children Sep 20, 2005 Ranbaxy gets US-FDA clearance to market Zidovudine tablets: Sep 20, 2005 FDA gives tentative approval to Indian AIDS drug Sep 11, 2005 First generic versions of AZT approved Sep 21, 2005 Black Health Experts Hail FDA Approval of Generic Drug for HIV ... Sep 22, 2005 Medical Report Sep 16, 2005 GLAXO'S PATENT PROTECTION ON FIRST AIDS DRUG, AZT, ENDS; AHF ... Sep 17, 2005 Business notebook Sep 20, 2005 US officials give tentative approval to Indian AIDS drug Sep 11, 2005 US clears oral AIDS drug for use overseas Sep 9, 2005 | ||
| Dosage Forms | tablets, capsules, injection | ||
| Drug_Category | Cardiotonic Agents; Antiarrhythmic Agents; ATC:C01AA02; ATC:C01AA05; ATC:C01AA08 | ||
| Absorption | Absorption of digoxin from the elixir pediatric formulation has been demonstrated to be 70% to 85% complete (90% to 100% from the capsules, and 60% to 80% for tablets). | ||
| Interactions |
Interactions for Digoxin: Potassium-depleting diuretics are a major contributing factor to digitalis toxicity. Calcium, particularly if administered rapidly by the intravenous route, may produce serious arrhythmias in digitalized patients. Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result. The risk of this interaction may be reduced if digoxin is given as capsules. Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption. Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations. Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin. There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration. Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin. Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias. Succinylcholine may cause a sudden extrusion of potassium from muscle cells, and may thereby cause arrhythmias in digitalized patients. Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block. Due to the considerable variability of these interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently. Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin. | ||
| Toxicity | Toxicity include ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block, LD50 = 7.8 mg/kg (orally in mice). | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 4-[3-[5-[5-(4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl)oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one | ||
| Chemical Formula | C41H64O14 | ||
| Molecular Weight | 780.938 g/mol | ||
| Smiles String | CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O | ||
| Melting Point | 248 - 250 °C | ||
| Water Solubility | Insoluble | ||
| State | Solid | ||
| LogP/Hphobicity | 1.969 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic (but not dependent upon the cytochrome P-450 system). The end metabolites, which include 3 b-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation. | ||
| Half Life | 3.5 to 5 days | ||
| Protein Binding [%] | 25% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Digoxin.html http://www.rxlist.com/cgi/generic/dig.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00098 | ||
| CAS Registry Number | 20830-75-5 | ||
| KEGG Compound ID | C06956 | ||
| PubChem ID | SID:64198 | ||
| PharmGKB ID | PA449319 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2242323 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |